Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies

Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies

Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
RestartResume

Learn more about the role of PSMA-targeted therapies in the treatment of metastatic castration-resistant prostate cancer.

Available credits: 1.00

Time to complete: 60 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).

    In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies.  An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Ayse Tuba Kendi, MD, reported a financial interest/relationship or affiliation in the form of Advisory board; Novartis Pharmaceuticals Corporation. Research grant; Novartis Pharmaceuticals Corporation.                                                

    Oliver Sartor, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Advanced Accelerator Applications; Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; Bayer; Blue Earth Diagnostics, Inc; Bavarian Nordic; Bristol-Myers Squibb Co; Clarity Pharmaceuticals; Clovis Oncology; Constellation, Dendreon Corp; EMD Serono, Inc; Fusion; Isotopen Technologien Meunchen; Janssen; Myovant; Myriad; Noria Therapeutics, Inc; Novartis Pharmaceuticals Corp; Noxopharm; Progenics Pharmaceuticals, Inc; POINT Biopharma; Pfizer, Inc; Sanofi; Tenebio; Telix; and Theragnostics. Research grant: Advanced Accelerator Applications; Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck & Co, Inc; Progenics; and Tenebio.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for medical oncologists, radiation oncologists, radiologists, urologists, urologic oncologists, surgeons, oncology nurses, nurse practitioners, pharmacists, physician assistants, and other healthcare professionals who are part of the interprofessional team responsible for the diagnosis and therapeutic management of prostate cancer.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Describe the clinical significance of the background and use of PSMA-based imaging for PET/CT for diagnosis of mCRPC
    2. Evaluate clinical trial data and research findings in the determination of best-practice selection and sequencing of available and emerging treatment modalities for patients with mCRPC
    3. Recognize the potential application of both PSMA-directed PET for diagnostics and PSMA-directed RLT for treatment
    4. Identify the patients who may benefit from a theranostic approach to slow tumor progression
    5. Apply strategies to identify and manage adverse events associated with investigative emerging therapies for mCRPC
    6. Summarize the potential impact of QoL improvements and other clinical challenges in patients with heavily pretreated mCRPC
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until August 31st, 2023. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hours of continuing pharmacy education JA4008106-0000-22-030-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

  • Activity Credit(s) and Certificate(s)

    Method of Participation and Request for Credit
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free